How many 8-K filings has Collegium Pharmaceutical, Inc filed?

Collegium Pharmaceutical, Inc (COLL) has 19 8-K (Current Event Report) filings on record, spanning Jan 2024 to Apr 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Collegium Pharmaceutical, Inc 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Collegium Pharmaceutical, Inc 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Collegium Pharmaceutical, Inc (COLL) — 8-K Filings

All 8-K filings from Collegium Pharmaceutical, Inc. Browse 19 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (19)

Collegium Pharmaceutical Announces Executive Changes — Apr 7, 2026 Risk: medium
Collegium Pharmaceutical, Inc. announced on April 2, 2026, a change in its executive team. Specifically, the company reported the departure of certain officers
8-K Filing — Dec 30, 2025
Collegium Pharmaceutical Files 8-K — Jul 7, 2025 Risk: low
On July 1, 2025, Collegium Pharmaceutical, Inc. filed an 8-K report. The filing indicates no specific material events or changes requiring immediate disclosure
Collegium Pharmaceutical Files 8-K on Officer/Director Changes — May 19, 2025 Risk: medium
On May 15, 2025, Collegium Pharmaceutical, Inc. filed an 8-K report detailing several key events. These include the departure of directors or certain officers,
Collegium Pharmaceutical Files 8-K: Other Events — May 12, 2025 Risk: medium
On May 12, 2025, Collegium Pharmaceutical, Inc. filed an 8-K report. The filing indicates an "Other Events" item, but the specific details of this event, includ
Collegium Pharma Elects New Directors, Adjusts Officer Compensation — Mar 17, 2025 Risk: medium
Collegium Pharmaceutical, Inc. announced on March 11, 2025, a change in its board of directors. Specifically, the company elected two new directors, Dr. Andrew
Collegetium Pharma Elects New Directors, Updates Exec Pay — Feb 5, 2025 Risk: low
Collegium Pharmaceutical, Inc. announced on February 3, 2025, changes in its board of directors and executive compensation. Specifically, the company elected tw
Collegium Pharmaceutical Files 8-K Report — Jan 8, 2025 Risk: low
On January 8, 2025, Collegium Pharmaceutical, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation
Collegium Pharma Reports Director Changes & Financial Updates — Nov 7, 2024 Risk: medium
On November 6, 2024, Collegium Pharmaceutical, Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Richar
Collegium Pharma Completes BioDelivery Sciences Acquisition — Sep 4, 2024 Risk: medium
On September 3, 2024, Collegium Pharmaceutical, Inc. announced the completion of its acquisition of all outstanding shares of BioDelivery Sciences International
Collegium Pharma Reports Material Agreement, Officer Changes — Jul 29, 2024 Risk: medium
On July 28, 2024, Collegium Pharmaceutical, Inc. entered into a material definitive agreement related to its results of operations and financial condition. The
Collegium Pharmaceutical Files 8-K — Jun 13, 2024 Risk: low
On June 13, 2024, Collegium Pharmaceutical, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corpor
Collegium Pharma Reports Director Departure, New CMO — May 24, 2024 Risk: low
On May 24, 2024, Collegium Pharmaceutical, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the co
Collegium Pharmaceutical Files 8-K on Security Holder Vote — May 20, 2024 Risk: low
On May 16, 2024, Collegium Pharmaceutical, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The filing does not contai
Collegium Pharmaceutical Files 8-K Report — May 13, 2024 Risk: low
On May 13, 2024, Collegium Pharmaceutical, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific transactions or f
Collegiate Pharmaceutical Appoints New CFO — May 10, 2024 Risk: medium
Collegiate Pharmaceutical, Inc. announced on May 9, 2024, the appointment of Michael Miller as Chief Financial Officer, effective May 13, 2024. Miller will rece
Collegium Pharmaceutical Enters Material Definitive Agreement — Apr 29, 2024 Risk: medium
On April 26, 2024, Collegium Pharmaceutical, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement,
Collegium Pharmaceutical Files 8-K — Apr 11, 2024 Risk: low
On April 11, 2024, Collegium Pharmaceutical, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, indicating
COLLEGIUM PHARMACEUTICAL Files Routine 8-K on Jan 1 Event — Jan 3, 2024
COLLEGIUM PHARMACEUTICAL, INC. filed an 8-K on January 3, 2024, reporting an event that occurred on January 1, 2024. This filing is a routine current report, in

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX